ClinicalTrials.gg
TerminatedNCT04109482Updated Jul 22, 2024

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

A Phase 1/2 interventional study of MB-102 and Fludarabine in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Mustang Bio. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Mustang Bio · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Business reasons.

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. Blastic Plasmacytoid Dendritic Cell Neoplasm · United States.

Enrollment
28th of 31
3 · median 45
Started
2020
with 5 others
Phase 1/2
4 of 33
none open now
Registered
21st of 33
by date
Lead sponsor
2 of 33
Mustang Bio

Among the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2020, is one of 4 in phase 1/2, and was the 21st registered.

Blastic Plasmacytoid Dendritic Cell Neoplasm

45 studies on the registry are indexed under Blastic Plasmacytoid Dendritic Cell Neoplasm; 15 are open to participants now.

Browse Blastic Plasmacytoid Dendritic Cell Neoplasm studies →

Open to participants now

9 of the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Blastic Plasmacytoid Dendritic Cell Neoplasm studies recruiting now, 7 (50%) set no upper age limit and 6 (43%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, or all of them as a file.
02

Study summary

A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN

Read the detailed description

The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102.

The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN.

03

Conditions studied

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Keywords

  • CD123 CAR-T
  • BPDCN
  • Blastic plasmacytoid dendritic cell neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Blastic Plasmacytoid Dendritic Cell Neoplasm

  1. Patients with a diagnosis of BPDCN according to WHO classification (Arber et al., 2016) confirmed by hematopathology and histological/cytological evidence of BPDCN in the peripheral blood, bone marrow, spleen, lymph nodes, skin and/or other sites who have failed one prior therapy.

    General Inclusion Criteria

  2. Male and female patients ≥ 18 years of age at the time of consent.
  3. Written in accordance with federal, local, and institutional guidelines.
  4. Must be able to adhere to the study visit schedule and other protocol requirements.
  5. Have an (ECOG) performance status of 0 or 1.
  6. Meet the following laboratory criteria:

    • Absolute lymphocyte count (ALC) > 100/mm3
    • /SGPT and AST/SGOT \< 2.5x the (ULN) unless due to underlying disease state
    • Calculated ≥ 45.0 mL/min as estimated by Cockcroft Gault and dialysis independent
    • Total ≤ 3.0 mg/dL

      • Patients with Gilbert's Syndrome must have a total bilirubin \< 5.0 mg/dL.
    • Serum albumin ≥ 3.2 g/dL
  7. Cardiac ≥ 45%, with no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or if not available, a multigated acquisition scan (MUGA).
  8. Females participants of must have a negative serum test.
  9. Patients must agree to use a highly effective method of if procreative potential exists from the start of the study until one year after the completion of lymphodepletion for females and 4 months after completion of lymphodepletion for males.
  10. Patients with a previously treated if treatment of that malignancy was completed greater than 2 years before screening and the patient has no evidence of disease at the time of screening.
  11. Patients who have previously undergone allogenic or bone marrow transplants are allowed.
  12. Centrally confirmed CD-123 positivity on the bone marrow, or for patients without bone marrow involvement local pathology assessments within 28 days from Screening, showing evidence of CD-123 positivity of skin/lymph node .

Exclusion criteria

Exclusion Criteria:

  1. Patients with a dependence on doses greater than physiological replacement i.e., prednisone no more than 7.5 mg/day or hydrocortisone less than 12mg/m2/day.
  2. or to fludarabine or cyclophosphamide.
  3. Hypersensitivity or known history of allergic reactions attributed to tocilizumab, Cetuximab, or other anti-EGFR -monoclonal antibodies.
  4. Immunotherapy treatments within 28 days prior to leukapheresis.
  5. Previous treatment with anti-CD123 CAR-T treatment.

    • Previous treatment with non-CAR-T anti-CD123 agents is allowed e.g. tagraxofusp-erzs.
  6. Previous treatment with any other antileukemic or agent within 7 days of leukapheresis.

    • Hydroxyurea is allowed up to 3 days prior to leukapheresis.
  7. Patients with history or active seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or any disease with CNS involvement.
  8. Patients with known CNS leukemic involvement that are to intrathecal chemotherapy and/or cranio-spinal radiation that have NOT been effectively treated to complete remission (defined as \< 5 WBC/mm3 and no blasts in CSF).
  9. Patients with active (GVHD).
  10. Acute active infection

    • Patients being administered prophylactic antibiotics, antivirals, or antifungals are permitted.
  11. Patients who have any form of primary immunodeficiency, such as severe combined immunodeficiency disease, (HIV), or acquired immune deficiency syndrome (AIDS).
  12. Active infection with or C.
  13. Patients requiring supplemental oxygen or mechanical ventilation or oxygen saturation \< 92% on room air.

    • Patients with an oxygen saturation \< 92%, a pulmonary function test with a result of Diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥ 40% of predicted and a (FEV1) > 45% predicted will be accepted.
  14. Patients with decompensated hepatic cirrhosis/liver failure.
  15. Pregnant or lactating females.
  16. Any other medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give .
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Relapsed or Refractory BPDCN

    Treatment with MB-102.

    Biological: MB-102 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalMB-102

    The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen. Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered.

    Also known as: CD123 CAR-T

  • Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3 * A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min).

    Also known as: Fludara

  • Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3

    Also known as: Cytoxan

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety and Tolerability as measured by the number of patients with treatment related adverse events

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in Phase 1

    Time frame: 28 Days

  2. Phase 1: Maximum Tolerated Dose (MTD) and recommended Phase 2 dose

    To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose of MB-102

    Time frame: 28 Days

  3. Phase 2: Response Rate of patients with BPDCN

    Relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm is measured by a response rate which consists of Complete Response and clinical Complete Response and Complete Response with incomplete hematologic recovery (CR + CRc + CRi) at day 28 post infusion

    Time frame: up to 3 years

Secondary outcomes

  1. Phase 2: BPDCN - DOR

    Duration of Response

    Time frame: up to 3 years

  2. Phase 2: BPDCN - PFS

    Progression-Free Survival

    Time frame: up to 3 years

  3. Phase 2: BPDCN - OS

    overall survival

    Time frame: up to 3 years

  4. Phase 2: BPDCN - MRD

    CR MRD- Response Rate for patients with CR and CRi

    Time frame: up to 3 years

  5. Phase 2 - Adverse events

    Incidence of treatment-emergent AEs (TEAEs), including SAEs, therapy-related AEs or death.

    Time frame: up to 3 years

  6. Phase 2 -Change from Baseline in the European Organization for Research and Treatment (EORTC) QLQ-C 30 Version 3.0.

    The European Organization for Research and Treatment (EORTC) QLQ-C 30 Version 3.0 is an integrated, modular approach for evaluating the quality of life of patients participating in international clinical trials. The questionnaire is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of 5 multi-item scales (physical, role, social, emotional and cognitive functioning) and 9 single items (pain, fatigue, financial impact, appetite loss, nausea/vomiting, diarrhea, constipation, sleep disturbance and quality of life). It utilizes a four-point scales for the first 28 questions which are coded with response categories as "Not at all", "A little", "Quite a bit" and "Very much.". the final two question consist of an overall physical condition questions which have employed a 7-point response scale where the higher number indicates a better overall health.

    Time frame: up to 3 years

  7. Phase 2 - Change from Baseline in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Version 4.0.

    The Functional Assessment of Cancer treatment for cancer, and a transplant-specific module, bone marrow transplant (BMT) concerns, that addresses disease and treatment-related questions specific to BMT. It utilizes a 5 point scale assessing physical, social, emotional, functional and other well-being concerns. Response categories are coded as "Not at all", "A little bit", "Somewhat", "Quite a bit" and "Very much.".

    Time frame: up to 3 years

  8. Phase 2 - Number of patients showing evidence of replication competent lentivirus

    To confirm the absence of replication competent lentivirus

    Time frame: up to 3 years

07

Study locations

4 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in May 2023, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 30, 2019
StartActual
Feb 17, 2020
Primary completionActual
May 17, 2023
CompletionActual
May 17, 2023
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04109482
Lead sponsor
Mustang Bio
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Feb 17, 2020
Primary completion
May 17, 2023
Completion
May 17, 2023
Last update
Jul 22, 2024

Study contacts

Lihua E Budde, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relmapirazin

Start the discussion